Single-cell and Bulk RNA-Seq Reveal Angiogenic Heterogeneity and Microenvironmental Features to Evaluate Prognosis and Therapeutic Response in Lung Adenocarcinoma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Feb 23

PMID 38390340

Authors

Lijuan Tang

Zhike Chen

Jian Yang

Qifan Li

Sichu Wang

Taoming Mo

Weibiao Zeng

Hao Ding

Shu Pan

Affiliations

Soon will be listed here.

Abstract

Background: Angiogenesis stands as a pivotal hallmark in lung adenocarcinoma (LUAD), intricately shaping the tumor microenvironment (TME) and influencing LUAD progression. It emerges as a promising therapeutic target for LUAD, affecting patients' prognosis. However, its role in TME, LUAD prognosis, and its clinical applicability remain shrouded in mystery.

Methods: We employed integrated single-cell and bulk transcriptome sequencing to unravel the heterogeneity of angiogenesis within LUAD cells. Through "consensus clustering", we delineated distinct angiogenic clusters and deciphered their TME features. "Monocle2" was used to unravel divergent trajectories within malignant cell subpopulations of LUAD. Additionally, regulon submodules and specific cellular communication patterns of cells in different angiogenic states were analyzed by "pyscenic" and "Cellchat" algorithms. The "univariate Cox" and "LASSO" algorithms were applied to build angiogenic prognostic models. Immunohistochemistry (IHC) on clinical samples validated the role of model factors in LUAD angiogenesis. We utilized CTRP 2.0 and PRISM databases for pinpointing sensitive drugs against lung adenocarcinoma.

Results: Two clusters for the activation of angiogenesis were identified, with Cluster 1 showing a poor prognosis and a pro-cancerous TME. Three differentiated states of malignant epithelial LUAD cells were identified, which had different degrees of angiogenic activation, were regulated by three different regulon submodules, and had completely different crosstalk from other cells in TME. The experiments validate that SLC2A1 promotes angiogenesis in LUAD. ARS (Angiogenesis related score) had a high prognostic value; low ARSs showed immunotherapy benefits, whereas high ARSs were sensitive to 15 chemotherapeutic agents.

Conclusion: The assessment of angiogenic clusters helps to determine the prognostic and TME characteristics of LUAD. Angiogenic prognostic models can be used to assess the prognosis, immunotherapeutic response, and chemotherapeutic drug sensitivity of LUAD.

Citing Articles

Comprehensive multi-omics analysis identifies NUSAP1 as a potential prognostic and immunotherapeutic marker for lung adenocarcinoma.

Ma J, Zhu W, Wang Y, Du H, Ma L, Liu L Int J Med Sci. 2025; 22(2):328-340.

PMID: 39781524 PMC: 11704694. DOI: 10.7150/ijms.102331.

Extracellular Vesicles from Lung Adenocarcinoma Cells Induce Activation of Different Cancer-Associated Fibroblast Subtypes.

Trejo Vazquez J, Towle R, Farnsworth D, Sarafan M, Lockwood W, Garnis C Biomedicines. 2024; 12(11).

PMID: 39595089 PMC: 11591910. DOI: 10.3390/biomedicines12112523.

FANCA promotes lung adenocarcinoma progression and is a potential target for epitope vaccine immunotherapy.

Kang Y, Zhong R, Gan Y, You J, Chen J, Chen F J Transl Med. 2024; 22(1):911.

PMID: 39375712 PMC: 11460194. DOI: 10.1186/s12967-024-05675-w.

References

Dong Z, Zhong W, Zhang X, Su J, Xie Z, Liu S . Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017; 23(12):3012-3024. DOI: 10.1158/1078-0432.CCR-16-2554. View

Han C, Zhang C, Wang H, Li K, Zhao L . Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma. BMC Cancer. 2021; 21(1):1312. PMC: 8653638. DOI: 10.1186/s12885-021-08987-y. View

Ren S, Xiong X, You H, Shen J, Zhou P . The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer. Front Immunol. 2021; 12:689132. PMC: 8206805. DOI: 10.3389/fimmu.2021.689132. View

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

Chen Z, Yang J, Tang L, Sun X, Li Y, Sheng Z . SUMOylation patterns and signature characterize the tumor microenvironment and predict prognosis in lung adenocarcinoma. Front Cell Dev Biol. 2023; 11:1094588. PMC: 10133499. DOI: 10.3389/fcell.2023.1094588. View

Liu Z, Gao W . Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017; 335:16-27. PMC: 5643250. DOI: 10.1016/j.taap.2017.09.017. View

Albini A, Bruno A, Noonan D, Mortara L . Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy. Front Immunol. 2018; 9:527. PMC: 5895776. DOI: 10.3389/fimmu.2018.00527. View

Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A . Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019; 18(1):60. PMC: 6441150. DOI: 10.1186/s12943-019-0974-6. View

Dagogo-Jack I, Shaw A . Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2017; 15(2):81-94. DOI: 10.1038/nrclinonc.2017.166. View

10.

Wang L, Lu Y, Wang C, Xie Y, Zhao Y, Qian Y . HB-EGF Activates the EGFR/HIF-1α Pathway to Induce Proliferation of Arsenic-Transformed Cells and Tumor Growth. Front Oncol. 2020; 10:1019. PMC: 7338480. DOI: 10.3389/fonc.2020.01019. View

11.

Anderson N, Simon M . The tumor microenvironment. Curr Biol. 2020; 30(16):R921-R925. PMC: 8194051. DOI: 10.1016/j.cub.2020.06.081. View

12.

Livingstone C . IGF2 and cancer. Endocr Relat Cancer. 2013; 20(6):R321-39. DOI: 10.1530/ERC-13-0231. View

13.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

14.

Yang X, Li C, Xu M, Zhao H, Wang D . Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis. BMC Cancer. 2015; 15:949. PMC: 4682247. DOI: 10.1186/s12885-015-1978-2. View

15.

Chen J, Tan Y, Sun F, Hou L, Zhang C, Ge T . Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer. Genome Biol. 2020; 21(1):152. PMC: 7315523. DOI: 10.1186/s13059-020-02064-6. View

16.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

17.

Delprat V, Tellier C, Demazy C, Raes M, Feron O, Michiels C . Cycling hypoxia promotes a pro-inflammatory phenotype in macrophages via JNK/p65 signaling pathway. Sci Rep. 2020; 10(1):882. PMC: 6972721. DOI: 10.1038/s41598-020-57677-5. View

18.

Wang X, Miao J, Wang S, Shen R, Zhang S, Tian Y . Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells. Mol Cancer. 2022; 21(1):133. PMC: 9214989. DOI: 10.1186/s12943-022-01596-8. View

19.

Meng Z, Li F, Fang C, Yeoman B, Qiu Y, Wang Y . The Hippo pathway mediates Semaphorin signaling. Sci Adv. 2022; 8(21):eabl9806. PMC: 9132450. DOI: 10.1126/sciadv.abl9806. View

20.

Chen X, Song E . Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2018; 18(2):99-115. DOI: 10.1038/s41573-018-0004-1. View